News

The American College of Gastroenterology has developed a clinical guideline for managing irritable bowel syndrome that addresses 25 key questions based on the strength and quality of evidence from medical literature.
Authors of a new study determined whether patients with irritable bowel syndrome could experience symptom relief with fecal microbiota transplantation from a single donor with a favorable microbiota profile. The findings were presented at UEG Week 2019.
The authors of a new study evaluated more than 4000 cases of Campylobacter infection to estimate the US incidence of Campylobacter infection–associated postinfectious irritable bowel syndrome.
The American Gastroenterological Association’s guideline applies to the evaluation of patients who are immunocompetent and who have had “watery” diarrhea for at least 4 weeks.
The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
Sarah Ballou, PhD, answers our questions about her research on the effects of IBS on daily function between disease subtypes, as well as about current IBS management challenges and more.
In this commentary, Brian E. Lacy, MD, PhD, from the Mayo Clinic, describes an holistic approach for managing IBS, how gastroenterologists can approach discussing psychological therapeutic options with their patients, and more.
Rachel Adams, MS, RD, answers our questions on her research about how individuals with irritable bowel syndrome relate their symptoms to diet, as well as the role of diet in the overall management of the condition.
Due to their prominent position in day-to-day patient care, NPs and PAs can play a key role in the prompt diagnosis and provision of effective care for patients with IBS.
Marissa Holden, an MD candidate at the University of California, Los Angeles, answers our questions about a new study that evaluated the relationship between the autonomic nervous system and bowel function, gut microbiota, and cortisol response in irritable bowel syndrome.